Nir Gomel, Rossella D'Aloisio, Aya Wattad, Rodolfo Mastropasqua, Federico Formenti, Anat Loewenstein, Matias Iglicki, Dinah Zur
{"title":"GOOD INITIAL VISUAL ACUITY IN PATIENTS WITH MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION: Management and Outcomes.","authors":"Nir Gomel, Rossella D'Aloisio, Aya Wattad, Rodolfo Mastropasqua, Federico Formenti, Anat Loewenstein, Matias Iglicki, Dinah Zur","doi":"10.1097/IAE.0000000000004244","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The approach to managing patients with retinal vein occlusion and cystoid macular edema (CME) with good initial visual acuity better than 6/12 has not been investigated. This study aimed to evaluate functional and anatomical outcomes of intravitreal treatment and observation in patients with CME because of retinal vein occlusion, who presented with good initial visual acuity.</p><p><strong>Methods: </strong>Multicenter retrospective cohort study. Seventy-nine eyes of 79 patients with CME secondary to retinal vein occlusion and initial visual acuity better than 6/12, either treated with antivascular endothelial growth factor therapy or observed. Clinical parameters and optical coherence tomography measures were recorded. Main Outcome Measure: Proportion of patients losing ≥1 line of visual acuity at 12 months. Secondary outcomes: visual and anatomical results at 12 months and 24 months, and correlation between number of injections and visual acuity outcomes.</p><p><strong>Results: </strong>Fifty-three percent of patients maintained visual acuity at month 12. Visual acuity of 6/6 to 6/7.5 was maintained in 59% and 57% at 12 months and 24 months, respectively. At 24 months, the number of antivascular endothelial growth factor injections was strongly correlated with visual acuity among patients with branch retinal vein occlusion and central retinal vein occlusion.</p><p><strong>Conclusion: </strong>This study marks the first exploration of patients with retinal vein occlusion and initial visual acuity better than 6/12, indicating that most patients sustained good visual acuity, and antivascular endothelial growth factor treatment maintained and improved visual acuity.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"2177-2184"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004244","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The approach to managing patients with retinal vein occlusion and cystoid macular edema (CME) with good initial visual acuity better than 6/12 has not been investigated. This study aimed to evaluate functional and anatomical outcomes of intravitreal treatment and observation in patients with CME because of retinal vein occlusion, who presented with good initial visual acuity.
Methods: Multicenter retrospective cohort study. Seventy-nine eyes of 79 patients with CME secondary to retinal vein occlusion and initial visual acuity better than 6/12, either treated with antivascular endothelial growth factor therapy or observed. Clinical parameters and optical coherence tomography measures were recorded. Main Outcome Measure: Proportion of patients losing ≥1 line of visual acuity at 12 months. Secondary outcomes: visual and anatomical results at 12 months and 24 months, and correlation between number of injections and visual acuity outcomes.
Results: Fifty-three percent of patients maintained visual acuity at month 12. Visual acuity of 6/6 to 6/7.5 was maintained in 59% and 57% at 12 months and 24 months, respectively. At 24 months, the number of antivascular endothelial growth factor injections was strongly correlated with visual acuity among patients with branch retinal vein occlusion and central retinal vein occlusion.
Conclusion: This study marks the first exploration of patients with retinal vein occlusion and initial visual acuity better than 6/12, indicating that most patients sustained good visual acuity, and antivascular endothelial growth factor treatment maintained and improved visual acuity.
期刊介绍:
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.